Promising combo tackles resistant breast cancer in phase 3 trial
NCT ID NCT07382687
First seen Feb 03, 2026 · Last updated Apr 28, 2026 · Updated 13 times
Summary
This phase 3 trial tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with advanced HR+/HER2- breast cancer that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The main goal is to see how long the cancer stays under control, while also checking safety and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.